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designed including 5 elements deﬁning quality, clustered into
three criteria, and 12 components covering types of evidence
required by decision-making bodies worldwide. A scoring
process was developed based on international scientiﬁc standards
in each ﬁeld of research covered. To quantify the intrinsic value
of an intervention, a multi-criteria decision analysis (MCDA)
matrix was designed encompassing 15 value components.
Scoring, which depends on the value system of the evaluator, was
designed to allow inclusion of perspectives of a representative
group of health care stakeholders. An integrated process to apply
matrices was established. The EVIDEM methodology can be
applied retrospectively to explore the contribution of quality of
evidence and intrinsic value to past coverage decisions. Prospec-
tively, matrices can be adapted to speciﬁc needs of decision-
makers and applied to evaluate new health care interventions.
The matrices also provide a practical collaborative frame-
work for those who generate data and those who need data
to make decisions, ultimately facilitating future health care
decision-making.
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Adherence is an important element in the medical ﬁeld since it is
thought to be the link between treatment and outcomes. Adher-
ence to medications has been extensively researched and it is
evident that non-adherence is common across most disease
states. These studies vary by the conceptual deﬁnitions of adher-
ence behavior and by the research paradigms. The objectives of
this presentation are to review the conceptual deﬁnitions used in
adherence research and to review the theoretical frameworks
used to explain mediation adherence behavior. Compliance,
adherence, and concordance are used interchangeably in the
medical, health behavior, and pharmacy literature. It is important
to compare and contrast these terms to study speciﬁc health
behavior. These terms reﬂect different philosophies of medicine
with respect to the provider-patient relationship. Conceptually,
adherence, compliance and concordance differ in the amount of
patient involvement and participation, that may be depicted
along a continuum of patient involvement- with compliance
depicting no patient involvement, concordance depicting patients
as being equal partners in their treatment and adherence lying
somewhere in between. Consistent use of these concepts will
move the science toward understanding speciﬁc patient behavior
and its antecedents.
Much of the adherence research published in the medical and
pharmacy journals does not include a theoretical framework.
The non-theoretical approach to adherence research is partly to
blame for the lack conceptual clarity and underscores the need to
incorporate a theoretical basis in adherence research. Prominent
theories in adherence research include expectancy-values models
like the health belief model, the transtheoretical model, and the
self-regulation theory. Other promising models include the medi-
cation adherence model, the interaction model of client behavior
and the therapeutic decision model. The strengths and weak-
nesses of each are presented. Finally, recommendations for
researchers of medication adherence include using a theoretical
framework and conducting longitudinal studies are provided.
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OBJECTIVE: Clinical evidence is often reported as an average
treatment effect across a large population. This is appropriate if
all patients experience the same effect from a given treatment.
However, more often, different patients experience different
outcomes on the same medication. If this is true, then averaging
the effects of treatment obscures the outcomes received by most
patients. It also makes it difﬁcult for physicians to utilize this
evidence to select the most appropriate treatment for individual
patients. This interpretation of average outcomes by physicians
leads to geographic variation, inappropriate care, and increased
health care costs. An essential step towards optimizing therapy
is to provide evidence that recognizes inter-individual differ-
ences in drug response. METHODS: The PPS is deﬁned as the
expected outcome (on control) given the individual’s covariates.
To calculate the PPS, the outcome of interest is regressed on the
covariates for those patients treated with the control(Drug A).
Using the coefﬁcients from this model, in conjunction with
patient characteristics, the PPS is computed for all patients; as
if every patient was a member of the control group. Variations
in treatment effect are then identiﬁed across subgroups by par-
titioning patients, according to PPS, into strata and calculat-
ing the treatment effect within each stratum. This analysis
is repeated using the alternative treatment (Drug B) as the
control. By identifying and comparing the stratum that receives
the optimal beneﬁt from each treatment, the patient character-
istics that are uniquely associated with success on Drug A and
Drug B can be determined. RESULTS: To demonstrate the use
of the PPS, a convenient sample of California Medicaid beneﬁ-
ciaries diagnosed with schizophrenia will be used. CONCLU-
SIONS: The outlined approach will allow physicians to more
accurately prescribe the most beneﬁcial treatment for each and
every patient, by linking patient characteristics to treatment
success.
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OBJECTIVES: The completion of the human genome project
has not provided the answer to genetic disease that was
expected and a large amount of research is still being con-
ducted into the treatment of genetically-linked disorders. The
rationale of this review was to investigate the proportion of
research conducted within eight genetically-linked disorders
across time (Alzheimer’s disease [AD], Crohn’s disease [CD],
cystic ﬁbrosis [CF], haemophilia, Huntington’s disease [HD],
muscular dystrophy [MD], Obesity, Sickle cell anaemia [SCA])
and to predict likely areas of growth within the selected disor-
ders. METHODS: A citation search was conducted in Medline
on December 12, 2007. A ﬁlter for RCTs was implemented to
provide an estimate of clinical interest in a given disease for the
years 1951–2005 (5-yearly time periods). RESULTS: A total of
706,660 probable RCT citations were retrieved, with 20,787
relating to the selected disorders. Over time, the rate of increase
of probable RCTs relating to these genetically-linked disorders
is not signiﬁcantly different from the general increase in RCTs
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